Valuation
- Market cap
- 718,666,000
- Revenue TTM
- $8,970,000
- Net income TTM
- $-400,670,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -4,466.78%
- Debt to equity
- -2.10
Trading
- Volume
- 4,886,100
- Avg volume
- 1,445,940
- Day's range
- $3.46 – $3.64
- Shares out
- 207,707,000
- Stochastic %K
- 55%
- Beta
- 0.79
- Analysts
- Strong Sell
- Price target
- $15.21
Company profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odip...
Show more
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 33 3 80 44 75 00
- Website
- https://inventivapharma.com
- Address
- 50 rue de Dijon, Daix, France
Latest news
No headlines yet.
